Table 1 ADAM-17 expression and clinical outcome of sorafenib treatment

From: MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents

 

ADAM-17 mRNA expression

P

High (n = 26)

Low (n = 26)

TTP

9.0

12.0

0.024

7.3–10.7 (M)

9.4–12.1 (M)

 

OS

10.0

13.0

0.033

6.6–11.4 (M)

10.8–14.6 (M)

 

Overall response rate (PR)

0 (0%)

4 (15.38%)

 

Disease control rate (PR + SD)

4 (15.38%)

9 (34.61%)

 
  1. CR complete remission, M months, OS overall survival, PR partial remission, SD stable of disease, TTP time to progress
Back to article page